Crystal form of ATX inhibitor or salt thereof as well as preparation method and application of crystal form
Patent Information
- Application Number
- CN202380026328.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-02
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-22
AI Technical Summary
Existing ATX inhibitors cannot effectively predict and slow down the progression of interstitial lung diseases, especially idiopathic pulmonary fibrosis. Traditional treatments focus on controlling symptoms and lack methods to significantly slow down the progression of the disease.
Provide different crystal forms of ATX inhibitors or their salts, including preparation methods of A, B, C, D, E crystal forms and their pharmaceutically acceptable salts, and achieve their crystallization through specific solvents and conditions to improve their physical and chemical properties and biological properties. Utilization.
These crystalline forms have advantages in melting point, solubility, stability, mechanical stability, etc., providing better choices for ATX inhibitor drug development and having important medical significance.
Smart Images

Figure CN119013273A_ABST
Abstract
Description
A crystalline form of an ATX inhibitor or its salt, and its preparation method and application Technical Field
[0001] The present invention belongs to the technical field of medicinal chemistry, and specifically relates to a crystalline form of an ATX inhibitor or a salt thereof, and a preparation method and application thereof. Background Art
[0002] Autotaxin (ATX) is a secreted lysophospholipase D (lysoPLD) that converts lysophosphatidylcholine (LPC) into the bioactive phospholipid derivative lysophosphatidic acid (LPA). LPA is the common name for acyl-hydroxy-glyceryl-3-phosphates, all composed of a phosphoglycerol backbone esterified to a single fatty acid, and exerts its biological activity by signaling through specific G protein-coupled receptors (LPA1-6). LPA mediates multiple fundamental responses to tissue injury, including responses that may be abnormal or excessive, causing tissue damage to lead to fibrosis rather than repair. LPA signaling, specifically through the LPA1 receptor, has profibrotic effects on epithelial cells, endothelial cells, and fibroblasts. On the other hand, LPA signaling through LPA2 is a negative regulator of innate immune responses, such as those mediated by dendritic cells in allergic lung inflammation. This activity of LPA may be required by the organism to prevent excessive inflammation following tissue injury. The ATX / LPA axis is involved in many physiological and pathological processes and is associated with a variety of diseases such as cancer, pain, cholestatic pruritus, fibrosis, inflammation, and cardiovascular disease.
[0003] Interstitial lung disease (ILD) encompasses a diverse group of conditions, with pulmonary inflammation and fibrosis being the common ultimate pathological pathways. Over 150 different factors contribute to ILD, including sarcoidosis, silicosis, drug reactions, infections, and collagen vascular diseases. Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD. IPF is a specific form of localized fibrotic interstitial pneumonia that, upon surgical lung biopsy analysis, exhibits a histopathological pattern resembling usual interstitial pneumonia (UIP). Most patients with IPF are over 50 years of age and present with insidious, progressive dyspnea and a nonproductive, dry cough over months to years. Pulmonary function assessment typically reveals reduced lung volumes, limited physiological function, decreased diffusion capacity, and hypoxemia after exercise. The progression of the disease is unpredictable, with variable rates of respiratory decline and progression to death. Deterioration may be rapid or gradual, or acute decline may occur during periods of stability.
[0004] Because fibrosis has long been considered a clinically irreversible process, traditional treatments have focused on controlling symptoms and complications, with little hope of significantly slowing disease progression. For many years, the mainstay of treatment for IPF has typically been the use of anti-inflammatory drugs, immunosuppressants, and antioxidants (e.g., corticosteroids, azathioprine, cyclophosphamide).
[0005] The applicant's PCT patent WO2022007882A1 provides a compound shown in the following formula, which has been found to have strong inhibitory activity against ATX.
[0006] Summary of the Invention
[0007] Problems to be solved by the invention
[0008] Since the existence form and quantity of polymorphic compounds are unpredictable, the present invention provides a crystalline form of an ATX inhibitor or a salt thereof as shown in formula (I), and a preparation method and application thereof.
[0009] Solutions for solving problems
[0010] The present invention provides a crystal form A of a compound represented by formula (I),
[0011] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 6.938, 7.606, 9.256, 12.359 and 15.793; preferably, characteristic peaks are present at 6.938, 7.606, 9.256, 9.912, 11.482, 12.359, 15.793 and 16.368; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG1 .
[0012] The present invention provides a crystal form B of a compound represented by formula (I),
[0013] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 7.593, 11.516, 13.092, 16.526 and 19.247; preferably, characteristic peaks are present at 7.593, 9.977, 11.516, 13.092, 15.380, 16.526, 19.247, 20.095, 23.854, 26.355, 27.639 and 29.809; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG3 .
[0014] The present invention provides a crystal form C of a compound represented by formula (I),
[0015] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 10.463, 10.666, 18.572, 20.708, 22.028 and 23.848; preferably at 10.463, 10.666, 13.970, 14.482, 15.220, 15.519, 17.747, 18.572, 20.708, 22.028 and 23.848 There are characteristic peaks; more preferably, there are characteristic peaks at 10.463, 10.666, 12.408, 13.970, 14.482, 15.220, 15.519, 17.747, 18.572, 20.708, 21.384, 22.028, 22.851, 23.848 and 25.788; most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 5.
[0016] The present invention provides a D crystal form of a compound represented by formula (I),
[0017] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 9.922, 11.176, 15.797, 16.230, 18.691 and 19.404; preferably at 7.514, 9.922, 11.176, 12.937, 15.797, 16.230, 18.691, 19.404, 20.310 and 21.224 There are characteristic peaks; more preferably, there are characteristic peaks at 7.514, 9.922, 11.176, 12.937, 15.797, 16.230, 17.219, 18.691, 19.404, 20.310, 21.224, 23.476, 24.003 and 24.627; most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 7.
[0018] The present invention provides a crystal form E of a compound represented by formula (I),
[0019] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 6.889, 9.043, 13.463, 15.828, 16.891 and 18.650; preferably, characteristic peaks at 5.164, 6.889, 8.818, 9.043, 13.463, 13.722, 15.828, 16.394, 16.891, 18.650 and 20.464 More preferably, there are characteristic peaks at 5.164, 6.889, 8.818, 9.043, 10.541, 13.463, 13.722, 15.828, 16.394, 16.891, 18.083, 18.650, 20.464, 22.201, 22.871 and 23.627; Most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 9.
[0020] The present invention provides a pharmaceutically acceptable salt of a compound represented by formula (I), wherein the pharmaceutically acceptable salt is selected from hydrochloride, sulfate, phosphate, methanesulfonate, benzenesulfonate, and p-toluenesulfonate.
[0021] In some embodiments, the chemical ratio of the compound represented by formula (I) to the acid molecule or anion is 1:0.5 to 1:3, which can be 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5, 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0022] The present invention provides a crystalline form I of a p-toluenesulfonate salt of a compound represented by formula (I).
[0023] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 3.733, 7.394, 16.080 and 19.153; preferably, characteristic peaks at 3.733, 7.394, 11.052, 14.739, 15.496, 16.080, 19.153, 22.059 and 28.088; more preferably, characteristic peaks at 3.733, 7.3 There are characteristic peaks at 94, 9.755, 11.052, 11.438, 12.185, 12.726, 13.220, 14.739, 15.496, 16.080, 17.180, 18.240, 19.153, 22.059 and 28.088; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 11.
[0024] The present invention provides a p-toluenesulfonate salt of a compound represented by formula (I) in crystal form II.
[0025] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 12.163, 14.065, 17.303, 19.416, 20.532 and 22.762; preferably, characteristic peaks at 3.780, 7.640, 10.191, 10.897, 12.163, 12.781, 14.065, 16.237, 17.303, 19.416, 20.532 and 22.762; more preferably Characteristic peaks are selected at 3.780, 7.640, 10.191, 10.897, 12.163, 12.781, 14.065, 15.837, 16.237, 16.954, 17.303, 19.000, 19.416, 20.532, 20.906, 21.961, 22.286 and 22.762; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 13.
[0026] The present invention provides a hydrochloride salt of a compound represented by formula (I) in crystal form I.
[0027] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 8.761, 9.480, 10.635 and 17.422; preferably, characteristic peaks are present at 8.761, 9.480, 10.635, 15.425, 16.788, 17.422 and 22.750; and most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 19 .
[0028] The present invention provides a hydrochloride salt of a compound represented by formula (I) in crystal form II.
[0029] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 6.985, 11.691, 14.025, 16.680 and 17.536; preferably, characteristic peaks are present at 6.985, 11.691, 14.025, 16.680, 17.536, 18.259, 19.185, 21.121, 21.895 and 23.548; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 21 .
[0030] The present invention provides a sulfate crystal form I of a compound represented by formula (I),
[0031] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 3.326, 6.485, 12.875, 13.879 and 19.273; preferably, characteristic peaks at 3.326, 6.485, 8.601, 12.875, 13.879, 16.915, 17.835, 19.273, 19.920 and 22.486; more preferably, characteristic peaks at 3.3 There are characteristic peaks at 26, 6.485, 8.601, 12.003, 12.875, 13.879, 14.315, 15.454, 16.087, 16.915, 17.835, 19.273, 19.920, 22.486, 23.727 and 25.010; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 23.
[0032] The present invention provides a phosphate crystal form I of a compound represented by formula (I),
[0033] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 3.436, 6.784, 16.868, 18.478 and 20.264; preferably, characteristic peaks are present at 3.436, 6.028, 6.784, 13.507, 15.360, 16.868, 18.478, 20.264, 23.661 and 30.556; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 25 .
[0034] The present invention provides a crystalline form I of a mesylate salt of a compound represented by formula (I),
[0035] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 7.945, 8.540, 12.203, 13.820 and 20.863; preferably, characteristic peaks at 7.945, 8.540, 10.316, 10.621, 11.507, 12.203, 13.820, 14.579, 15.964 and 20.863; more preferably There are characteristic peaks at 7.945, 8.540, 10.316, 10.621, 11.507, 12.203, 13.820, 14.579, 15.964, 17.640, 20.284, 20.863, 23.234, 23.888 and 26.418; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 27.
[0036] The present invention provides a benzenesulfonate salt of a compound represented by formula (I) in crystal form I.
[0037] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 5.268, 6.306, 13.796, 15.768 and 18.673; preferably, there are characteristic peaks at 5.268, 6.306, 6.865, 13.796, 15.023, 15.768, 18.673, 21.035, 21.892 and 22.608; more preferably, there are characteristic peaks at 5. There are characteristic peaks at 268, 6.306, 6.865, 9.398, 11.030, 12.049, 13.796, 15.023, 15.768, 16.228, 17.946, 18.673, 20.835, 21.035, 21.892 and 22.608; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 29.
[0038] Effects of the Invention
[0039] The present invention provides crystal form A, crystal form B, crystal form C, crystal form D, crystal form E, p-toluenesulfonate, hydrochloride, sulfate, phosphate, methanesulfonate, benzenesulfonate, as well as crystal form I of p-toluenesulfonate, crystal form II of p-toluenesulfonate, crystal form I of hydrochloride, crystal form II of hydrochloride, crystal form I of sulfate, crystal form I of phosphate, crystal form I of methanesulfonate, and crystal form I of benzenesulfonate of the compound represented by formula (I). They have advantages in physical and chemical properties, formulation processing performance, and bioavailability, for example, advantages in at least one of melting point, solubility, hygroscopicity, purification effect, stability, adhesion, compressibility, flowability, in vitro and in vivo dissolution, and bioavailability. The free base crystal form, salt form, and crystal form of the salt form described in the present invention have good physical and chemical stability, and the yield of the corresponding crystal form prepared from the same starting materials is high. They also have obvious advantages in solubility, hygroscopicity, stability, mechanical stability, fluidity, compressibility, adhesion, drug metabolism, etc., providing a new and better option for the development of ATX inhibitor drugs, which is of great significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] FIG1 is an XRPD spectrum of Form A of the compound represented by formula (I).
[0041] Figure 2 is a TGA & DSC superposition spectrum of Form A of the compound represented by formula (I).
[0042] FIG3 is an XRPD spectrum of Form B of the compound represented by formula (I).
[0043] FIG4 is a TGA & DSC superposition spectrum of Form B of the compound represented by formula (I).
[0044] FIG5 is an XRPD spectrum of Form C of the compound represented by formula (I).
[0045] FIG6 is a TGA&DSC superposition spectrum of Form C of the compound represented by formula (I).
[0046] FIG7 is an XRPD spectrum of Form D of the compound represented by formula (I).
[0047] FIG8 is a DSC spectrum of the crystal form D of the compound represented by formula (I).
[0048] FIG9 is an XRPD spectrum of Form E of the compound represented by formula (I).
[0049] Figure 10 is a TGA & DSC superimposed spectrum of Form E of the compound represented by formula (I).
[0050] FIG11 is an XRPD spectrum of the p-toluenesulfonate salt of the compound represented by formula (I) in Form I.
[0051] Figure 12 is a TGA & DSC superimposed spectrum of the p-toluenesulfonate salt form I of the compound represented by formula (I).
[0052] FIG13 is an XRPD spectrum of the p-toluenesulfonate salt form II of the compound represented by formula (I).
[0053] FIG14 is a TGA & DSC superimposed spectrum of the p-toluenesulfonate II crystalline form of the compound represented by formula (I).
[0054] FIG15 is a DVS spectrum of the p-toluenesulfonate II crystalline form of the compound represented by formula (I).
[0055] FIG16 is an XRPD overlay of the p-toluenesulfonate salt form II of the compound represented by formula (I) before and after DVS testing.
[0056] FIG17 is an overlay of XRPD spectra of the solid obtained by wet grinding of Form B of the compound represented by formula (I).
[0057] FIG18 is an XRPD spectrum of the solid obtained by tableting Form B of the compound represented by formula (I).
[0058] FIG19 is an XRPD spectrum of Form I hydrochloride of the compound represented by formula (I).
[0059] Figure 20 is a TGA & DSC superimposed spectrum of the hydrochloride salt form I of the compound represented by formula (I).
[0060] FIG21 is an XRPD spectrum of the hydrochloride II crystal form of the compound represented by formula (I).
[0061] Figure 22 is a TGA & DSC superimposed spectrum of the hydrochloride II crystal form of the compound represented by formula (I).
[0062] FIG23 is an XRPD spectrum of the sulfate salt form I of the compound represented by formula (I).
[0063] Figure 24 is a TGA & DSC superimposed spectrum of the sulfate salt form I of the compound represented by formula (I).
[0064] FIG25 is an XRPD spectrum of the phosphate salt form I of the compound represented by formula (I).
[0065] Figure 26 is a TGA & DSC superimposed spectrum of the phosphate I crystal form of the compound represented by formula (I).
[0066] FIG27 is an XRPD spectrum of the mesylate salt Form I of the compound represented by formula (I).
[0067] Figure 28 is a TGA & DSC overlay spectrum of the mesylate salt form I of the compound represented by formula (I).
[0068] FIG29 is an XRPD spectrum of Form I of the benzenesulfonate salt of the compound represented by formula (I).
[0069] Figure 30 is a TGA & DSC overlay spectrum of the benzenesulfonate salt form I of the compound represented by formula (I). DETAILED DESCRIPTION
[0070] To make the technical solutions and beneficial effects of the present invention more clearly understood, the following detailed description is given by way of specific embodiments. The accompanying drawings are not necessarily drawn to scale, and local features may be enlarged or reduced to more clearly illustrate the details of the local features. Unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application belongs.
[0071] The present invention provides a crystal form A of a compound represented by formula (I),
[0072] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 6.938, 7.606, 9.256, 12.359 and 15.793; preferably, characteristic peaks are present at 6.938, 7.606, 9.256, 9.912, 11.482, 12.359, 15.793 and 16.368; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG1 .
[0073] The present invention further provides a method for preparing crystal form A of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with solvent 1, dissolving the mixture, adding solvent 2, and crystallizing.
[0074] In certain embodiments, the solvent 1 is selected from ether solvents.
[0075] In certain embodiments, the solvent 1 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane.
[0076] In certain embodiments, the solvent 1 is selected from 1,4-dioxane.
[0077] In certain embodiments, the solvent 2 is selected from alcohol solvents.
[0078] In certain embodiments, the solvent 2 is selected from C 1-4 alcohol.
[0079] In certain embodiments, the solvent 2 is selected from one or more of methanol, ethanol and isopropanol.
[0080] In certain embodiments, the solvent 2 is selected from isopropyl alcohol.
[0081] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0082] The present invention further provides a crystal form B of the compound represented by formula (I),
[0083] The X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ has characteristic peaks at 7.593, 11.516, 13.092, 16.526 and 19.247; preferably, characteristic peaks are present at 7.593, 9.977, 11.516, 13.092, 15.380, 16.526, 19.247, 20.095, 23.854, 26.355, 27.639 and 29.809; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle 2θ is shown in FIG3 .
[0084] The present invention further provides a method for preparing crystal form B of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with solvent 3, dissolving the mixture, adding solvent 4, and crystallizing.
[0085] In certain embodiments, the solvent 3 is selected from ether solvents.
[0086] In certain embodiments, the solvent 3 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane.
[0087] In certain embodiments, the solvent 3 is selected from 1,4-dioxane.
[0088] In certain embodiments, the solvent 4 is selected from nitrile solvents, preferably one or more of acetonitrile, propionitrile and valeronitrile, more preferably acetonitrile.
[0089] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0090] The present invention further provides a crystal form C of the compound represented by formula (I),
[0091] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 10.463, 10.666, 18.572, 20.708, 22.028 and 23.848; preferably at 10.463, 10.666, 13.970, 14.482, 15.220, 15.519, 17.747, 18.572, 20.708, 22.028 and 23.848 There are characteristic peaks; more preferably, there are characteristic peaks at 10.463, 10.666, 12.408, 13.970, 14.482, 15.220, 15.519, 17.747, 18.572, 20.708, 21.384, 22.028, 22.851, 23.848 and 25.788; most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 5.
[0092] The present invention further provides a method for preparing crystal form C of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 5, suspending, stirring, and filtering to obtain a filter cake.
[0093] In certain embodiments, the solvent 5 is selected from ether solvents.
[0094] In certain embodiments, the solvent 5 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and methyl tert-butyl ether.
[0095] In certain embodiments, the solvent 5 is selected from methyl tert-butyl ether.
[0096] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0097] The present invention further provides a D-type crystal of the compound represented by formula (I),
[0098] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 9.922, 11.176, 15.797, 16.230, 18.691 and 19.404; preferably at 7.514, 9.922, 11.176, 12.937, 15.797, 16.230, 18.691, 19.404, 20.310 and 21.224 There are characteristic peaks; more preferably, there are characteristic peaks at 7.514, 9.922, 11.176, 12.937, 15.797, 16.230, 17.219, 18.691, 19.404, 20.310, 21.224, 23.476, 24.003 and 24.627; most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 7.
[0099] The present invention further provides a method for preparing the D crystal form of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 6, sealing, placing, and filtering to obtain a filter cake.
[0100] In certain embodiments, the solvent 6 is selected from ether solvents.
[0101] In certain embodiments, the solvent 6 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane.
[0102] In certain embodiments, the solvent 6 is selected from 1,4-dioxane
[0103] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0104] The present invention further provides a crystalline form E of the compound represented by formula (I),
[0105] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 6.889, 9.043, 13.463, 15.828, 16.891 and 18.650; preferably, characteristic peaks at 5.164, 6.889, 8.818, 9.043, 13.463, 13.722, 15.828, 16.394, 16.891, 18.650 and 20.464 More preferably, there are characteristic peaks at 5.164, 6.889, 8.818, 9.043, 10.541, 13.463, 13.722, 15.828, 16.394, 16.891, 18.083, 18.650, 20.464, 22.201, 22.871 and 23.627; Most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 9.
[0106] The present invention further provides a method for preparing the E crystal form of the compound represented by formula (I), which is characterized by comprising the steps of: mixing the compound represented by formula (I) with solvent 7, dissolving, cooling, and crystallizing.
[0107] In certain embodiments, the solvent 7 is selected from ether solvents.
[0108] In certain embodiments, the solvent 7 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane.
[0109] In certain embodiments, the solvent 7 is selected from 1,4-dioxane.
[0110] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0111] The present invention further provides a pharmaceutically acceptable salt of the compound represented by formula (I), wherein the pharmaceutically acceptable salt is selected from p-toluenesulfonate, hydrochloride, sulfate, phosphate, methanesulfonate, benzenesulfonate,
[0112] In certain embodiments, the chemical ratio of the compound represented by formula (I) to the acid molecule or anion is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0113] In certain embodiments, the chemical ratio of the compound represented by formula (I) to p-toluenesulfonic acid is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0114] In certain embodiments, the chemical ratio of the compound of formula (I) to hydrochloric acid is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0115] In certain embodiments, the chemical ratio of the compound of formula (I) to sulfuric acid is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0116] In certain embodiments, the chemical ratio of the compound of formula (I) to phosphoric acid is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0117] In certain embodiments, the chemical ratio of the compound of formula (I) to methanesulfonic acid is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0118] In certain embodiments, the chemical ratio of the compound represented by formula (I) to benzenesulfonic acid is 1:0.5 to 1:3, for example, 1:0.5 to 1:2.5, 1:0.5 to 1:2, 1:0.5 to 1:1.5 or 1:0.5 to 1:1, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:2.
[0119] The present invention further provides a method for preparing a pharmaceutically acceptable salt of a compound represented by formula (I), comprising the steps of: reacting the compound represented by formula (I) with an acid to form a salt.
[0120] In certain embodiments, the solvent used in the salt-forming reaction is selected from one or more of alcohols, ethers, esters, halogenated alkanes, ketones and water.
[0121] In certain embodiments, the solvent used in the salt-forming reaction is selected from one or more of tetrahydrofuran, dichloromethane, ethanol, ethyl acetate, acetone and water.
[0122] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0123] The present invention further provides a crystalline form I of a p-toluenesulfonate salt of a compound represented by formula (I),
[0124] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 3.733, 7.394, 16.080 and 19.153; preferably, characteristic peaks at 3.733, 7.394, 11.052, 14.739, 15.496, 16.080, 19.153, 22.059 and 28.088; more preferably, characteristic peaks at 3.733, 7.3 There are characteristic peaks at 94, 9.755, 11.052, 11.438, 12.185, 12.726, 13.220, 14.739, 15.496, 16.080, 17.180, 18.240, 19.153, 22.059 and 28.088; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 11.
[0125] The present invention further provides a method for preparing a crystalline form I of a p-toluenesulfonate salt of a compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 8, placing the system in dry ice, adding p-toluenesulfonic acid monohydrate, stirring at room temperature, and crystallizing.
[0126] In certain embodiments, the solvent 8 is selected from ester solvents.
[0127] In certain embodiments, the solvent 8 is selected from one or more of ethyl acetate, methyl acetate, butyl acetate, and isobutyl acetate.
[0128] In certain embodiments, the solvent 8 is selected from ethyl acetate.
[0129] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0130] The present invention further provides a p-toluenesulfonate salt of a compound represented by formula (I) in crystal form II.
[0131] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 12.163, 14.065, 17.303, 19.416, 20.532 and 22.762; preferably, characteristic peaks at 3.780, 7.640, 10.191, 10.897, 12.163, 12.781, 14.065, 16.237, 17.303, 19.416, 20.532 and 22.762; more preferably Characteristic peaks are selected at 3.780, 7.640, 10.191, 10.897, 12.163, 12.781, 14.065, 15.837, 16.237, 16.954, 17.303, 19.000, 19.416, 20.532, 20.906, 21.961, 22.286 and 22.762; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 13.
[0132] The present invention further provides a method for preparing the crystal form II of the p-toluenesulfonate salt of the compound represented by formula (I), characterized in that it comprises the steps of: mixing the compound represented by formula (I) with solvent 9, placing the system in ice-ethanol, adding p-toluenesulfonic acid monohydrate, stirring overnight, and crystallizing.
[0133] In certain embodiments, the solvent 9 is selected from ester solvents.
[0134] In certain embodiments, the solvent 9 is selected from one or more of ethyl acetate, methyl acetate, butyl acetate, and isobutyl acetate.
[0135] In certain embodiments, the solvent 9 is selected from ethyl acetate.
[0136] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0137] The present invention further provides a hydrochloride salt of a compound represented by formula (I) in Form I.
[0138] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 8.761, 9.480, 10.635 and 17.422; preferably, characteristic peaks are present at 8.761, 9.480, 10.635, 15.425, 16.788, 17.422 and 22.750; and most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 19 .
[0139] The present invention further provides a method for preparing Form I of the hydrochloride salt of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 10, placing the system in dry ice, adding hydrochloric acid, stirring at room temperature, crystallizing, stirring overnight, and filtering.
[0140] In certain embodiments, the solvent 10 is selected from ether solvents.
[0141] In certain embodiments, the solvent 10 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and tetrahydrofuran.
[0142] In certain embodiments, the solvent 10 is selected from tetrahydrofuran.
[0143] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0144] The present invention further provides a hydrochloride salt of a compound represented by formula (I) in crystal form II.
[0145] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 6.985, 11.691, 14.025, 16.680 and 17.536; preferably, characteristic peaks are present at 6.985, 11.691, 14.025, 16.680, 17.536, 18.259, 19.185, 21.121, 21.895 and 23.548; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 21 .
[0146] The present invention further provides a method for preparing the crystal form II of the hydrochloride salt of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 11, placing the system in dry ice, adding hydrochloric acid, stirring at room temperature, evaporating the solvent in an open state, stirring after precipitating a solid, and filtering.
[0147] In certain embodiments, the solvent 11 is selected from a mixed solvent of halogenated alkanes and alcohol solvents.
[0148] In certain embodiments, the solvent 11 is a mixed solvent of halogenated alkanes selected from dichloromethane, chloroform, carbon tetrachloride and 1,2-dichloroethane and an alcohol solvent selected from methanol, ethanol and isopropanol.
[0149] In certain embodiments, the solvent 11 is selected from a mixed solvent of dichloromethane and ethanol.
[0150] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0151] The present invention further provides a sulfate crystal form I of the compound represented by formula (I),
[0152] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 3.326, 6.485, 12.875, 13.879 and 19.273; preferably, there are characteristic peaks at 3.326, 6.485, 8.601, 12.875, 13.879, 16.915, 17.835, 19.273, 19.920 and 22.486; more preferably, there are characteristic peaks at 3.326, 6.485, 8.601, 12.003, 12.875, 13.879, 14.315, 15.454, There are characteristic peaks at 16.087, 16.915, 17.835, 19.273, 19.920, 22.486, 23.727 and 25.010; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 23.
[0153] The present invention further provides a method for preparing crystal form I of the sulfate salt of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with solvent 12, placing the system in dry ice, adding sulfuric acid, stirring at room temperature, heating to 50° C. and stirring overnight, cooling to room temperature, and filtering.
[0154] In certain embodiments, the solvent 12 is selected from ketone solvents.
[0155] In certain embodiments, the solvent 12 is selected from one or more of acetone, butanone, pentanone, hexanone, and cyclohexanone.
[0156] In certain embodiments, the solvent 12 is selected from acetone.
[0157] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0158] The present invention further provides a crystalline form I of the phosphate of the compound represented by formula (I),
[0159] The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 3.436, 6.784, 16.868, 18.478 and 20.264; preferably, characteristic peaks are present at 3.436, 6.028, 6.784, 13.507, 15.360, 16.868, 18.478, 20.264, 23.661 and 30.556; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 25 .
[0160] The present invention further provides a method for preparing crystal form I of the phosphate of the compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with solvent 13, placing the system in dry ice, adding phosphoric acid, stirring at room temperature, heating to 50° C. and stirring, crystallizing, continuing stirring, cooling to room temperature and stirring overnight, and filtering.
[0161] In certain embodiments, the solvent 13 is selected from ester solvents.
[0162] In certain embodiments, the solvent 13 is selected from one or more of ethyl acetate, methyl acetate, butyl acetate, and isobutyl acetate.
[0163] In certain embodiments, the solvent 13 is selected from ethyl acetate.
[0164] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0165] The present invention further provides a crystalline form I of a mesylate salt of a compound represented by formula (I),
[0166] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 7.945, 8.540, 12.203, 13.820 and 20.863; preferably, characteristic peaks at 7.945, 8.540, 10.316, 10.621, 11.507, 12.203, 13.820, 14.579, 15.964 and 20.863; more preferably There are characteristic peaks at 7.945, 8.540, 10.316, 10.621, 11.507, 12.203, 13.820, 14.579, 15.964, 17.640, 20.284, 20.863, 23.234, 23.888 and 26.418; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 27.
[0167] The present invention further provides a method for preparing crystal form I of a mesylate salt of a compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 14, placing the system in dry ice, adding methanesulfonic acid, stirring at room temperature, heating to 50° C. with stirring, cooling to room temperature with open volatilization and stirring, crystallization, stirring, and filtering.
[0168] In certain embodiments, the solvent 14 is selected from ether solvents.
[0169] In certain embodiments, the solvent 14 is selected from one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and tetrahydrofuran.
[0170] In certain embodiments, the solvent 14 is selected from tetrahydrofuran.
[0171] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0172] The present invention further provides a crystalline form I of a benzenesulfonate salt of a compound represented by formula (I),
[0173] The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 5.268, 6.306, 13.796, 15.768 and 18.673; preferably, there are characteristic peaks at 5.268, 6.306, 6.865, 13.796, 15.023, 15.768, 18.673, 21.035, 21.892 and 22.608; more preferably, there are characteristic peaks at 5. There are characteristic peaks at 268, 6.306, 6.865, 9.398, 11.030, 12.049, 13.796, 15.023, 15.768, 16.228, 17.946, 18.673, 20.835, 21.035, 21.892 and 22.608; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 29.
[0174] The present invention further provides a method for preparing a crystalline form I of a benzenesulfonate salt of a compound represented by formula (I), comprising the steps of: mixing the compound represented by formula (I) with a solvent 15, placing the system in dry ice, adding benzenesulfonic acid, stirring at room temperature, heating to 50° C. and stirring to allow crystals to precipitate, continuing stirring, cooling to room temperature and stirring overnight, and filtering.
[0175] In certain embodiments, the solvent 15 is selected from ester solvents.
[0176] In certain embodiments, the solvent 15 is selected from one or more of ethyl acetate, methyl acetate, butyl acetate, and isobutyl acetate.
[0177] In certain embodiments, the solvent 15 is selected from ethyl acetate.
[0178] In certain embodiments, the preparation method of the present invention further comprises steps such as centrifugation, washing or drying.
[0179] The present invention further provides a pharmaceutical composition prepared from the aforementioned crystal form A of the compound represented by formula (I), the aforementioned crystal form B of the compound represented by formula (I), the aforementioned crystal form C of the compound represented by formula (I), the aforementioned crystal form D of the compound represented by formula (I), the aforementioned crystal form E of the compound represented by formula (I), the aforementioned pharmaceutically acceptable salt of the compound represented by formula (I), the aforementioned crystal form I of the p-toluenesulfonate salt of the compound represented by formula (I), the aforementioned crystal form II of the p-toluenesulfonate salt of the compound represented by formula (I), the aforementioned crystal form I of the hydrochloride salt of the compound represented by formula (I), the aforementioned crystal form II of the hydrochloride salt of the compound represented by formula (I), the aforementioned crystal form I of the sulfate salt of the compound represented by formula (I), the aforementioned crystal form I of the phosphate salt of the compound represented by formula (I), the aforementioned crystal form I of the methanesulfonate salt of the compound represented by formula (I), or the aforementioned crystal form I of the benzenesulfonate salt of the compound represented by formula (I).
[0180] The present invention further provides a pharmaceutical composition comprising the aforementioned crystalline form A of the compound represented by formula (I), the aforementioned crystalline form B of the compound represented by formula (I), the aforementioned crystalline form C of the compound represented by formula (I), the aforementioned crystalline form D of the compound represented by formula (I), the aforementioned crystalline form E of the compound represented by formula (I), the aforementioned pharmaceutically acceptable salt of the compound represented by formula (I), the aforementioned crystalline form I of the p-toluenesulfonate salt of the compound represented by formula (I), the aforementioned crystalline form II of the p-toluenesulfonate salt of the compound represented by formula (I), the aforementioned crystalline form I of the hydrochloride salt of the compound represented by formula (I), the aforementioned crystalline form II of the hydrochloride salt of the compound represented by formula (I), the aforementioned crystalline form I of the sulfate salt of the compound represented by formula (I), the aforementioned crystalline form I of the phosphate salt of the compound represented by formula (I), the aforementioned crystalline form I of the methanesulfonate salt of the compound represented by formula (I), or the aforementioned crystalline form I of the benzenesulfonate salt of the compound represented by formula (I), and at least one pharmaceutically acceptable excipient.
[0181] "Pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, mixture, or vehicle that contributes to the consistency of the dosage form or pharmaceutical composition. Suitable pharmaceutically acceptable excipients will vary depending on the dosage form selected. In addition, pharmaceutically acceptable excipients may be selected based on their specific function in the composition.
[0182] In certain embodiments, the pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, flavoring agents, taste masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasers, antioxidants, preservatives, stabilizers, surfactants and buffers.
[0183] In certain embodiments, the pharmaceutical composition is a solid preparation.
[0184] In certain embodiments, the solid dosage form is a capsule.
[0185] In certain embodiments, the capsule contains 25 mg to 200 mg of the compound represented by formula (I) or a salt thereof.
[0186] The present invention further provides a method for preparing a pharmaceutical composition, comprising the step of mixing the aforementioned crystal form A of the compound represented by formula (I), the aforementioned crystal form B of the compound represented by formula (I), the aforementioned crystal form C of the compound represented by formula (I), the aforementioned crystal form D of the compound represented by formula (I), the aforementioned crystal form E of the compound represented by formula (I), the aforementioned pharmaceutically acceptable salt of the compound represented by formula (I), the aforementioned crystal form I of the p-toluenesulfonate salt of the compound represented by formula (I), the aforementioned crystal form II of the p-toluenesulfonate salt of the compound represented by formula (I), the aforementioned crystal form I of the hydrochloride salt of the compound represented by formula (I), the aforementioned crystal form II of the hydrochloride salt of the compound represented by formula (I), the aforementioned crystal form I of the sulfate salt of the compound represented by formula (I), the aforementioned crystal form I of the phosphate salt of the compound represented by formula (I), the aforementioned crystal form I of the methanesulfonate salt of the compound represented by formula (I), or the aforementioned crystal form I of the benzenesulfonate salt of the compound represented by formula (I) with at least one pharmaceutically acceptable excipient.
[0187] The present invention further provides a crystalline form A of the compound represented by the aforementioned formula (I), or a crystalline form B of the compound represented by the aforementioned formula (I), or a crystalline form C of the compound represented by the aforementioned formula (I), or a crystalline form D of the compound represented by the aforementioned formula (I), or a crystalline form E of the compound represented by the aforementioned formula (I), or a pharmaceutically acceptable salt of the compound represented by the aforementioned formula (I), or a crystalline form I of a p-toluenesulfonate salt of the compound represented by the aforementioned formula (I), or a crystalline form II of a p-toluenesulfonate salt of the compound represented by the aforementioned formula (I), or a salt of the compound represented by the aforementioned formula (I). The invention relates to a pharmaceutical composition comprising the crystal form I of the hydrochloride salt of the compound represented by the aforementioned formula (I) or the crystal form II of the hydrochloride salt of the compound represented by the aforementioned formula (I) or the crystal form I of the sulfate salt of the compound represented by the aforementioned formula (I) or the crystal form I of the phosphate salt of the compound represented by the aforementioned formula (I) or the crystal form I of the methanesulfonate salt of the compound represented by the aforementioned formula (I) or the crystal form I of the benzenesulfonate salt of the compound represented by the aforementioned formula (I), or the aforementioned pharmaceutical composition, or the use of the pharmaceutical composition prepared by the aforementioned method in the preparation of a drug for treating and / or preventing ATX (autotaxin)-related diseases.
[0188] In certain embodiments, the ATX-related disease is a fibrotic disease, cancer, a proliferative disease, an inflammatory disease, an autoimmune disease, a respiratory disease, a cardiovascular disease, a neurodegenerative disease, a dermatological disease, a metabolic disease, a myelodysplastic syndrome, a disease associated with abnormal angiogenesis, or pain.
[0189] In certain embodiments, the ATX-related disease is a fibrotic disease, a cancer, or a dermatological disease.
[0190] In certain embodiments, the ATX-associated disease is pulmonary fibrosis (eg, idiopathic pulmonary fibrosis), liver fibrosis, scleroderma, renal cancer, pancreatic cancer, or cholestatic pruritus.
[0191] The "2θ or 2θ angle" mentioned in the present invention refers to the diffraction angle, θ is the Bragg angle, and the unit is ° or degree; the error range of each characteristic peak 2θ is ±0.2 (including the case where the number exceeding 1 decimal place is rounded off), which can be -0.20, -0.19, -0.18, -0.17, -0.16, -0.15, -0.14, -0.13, -0.12, -0.11, -0.10, -0.09, - 0.08, -0.07, -0.06, -0.05, -0.04, -0.03, -0.02, -0.01, 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20.
[0192] The precipitation methods of the present invention include but are not limited to stirring, cooling, volatilization, beating, and precipitation.
[0193] "Pulping" is a common term in the field of drug preparation, which usually refers to the mechanization or fluidization of solid drug raw materials so that the solid drug is dispersed or suspended in a solvent.
[0194] In some embodiments, the beating time is 5 hours to 30 hours.
[0195] According to the description of hygroscopic characteristics and the definition of hygroscopic weight gain in the "9103 Guiding Principles for Hygroscopicity of Drugs" in Part IV of the 2015 edition of the Chinese Pharmacopoeia,
[0196] Deliquescent: Absorbs sufficient water to form a liquid;
[0197] Highly hygroscopic: weight gain due to moisture absorption is not less than 15%;
[0198] Hygroscopic: weight gain due to moisture absorption is less than 15% but not less than 2%;
[0199] Slightly hygroscopic: weight gain due to moisture absorption is less than 2% but not less than 0.2%;
[0200] No or almost no hygroscopicity: weight gain due to moisture is less than 0.2%.
[0201] The "differential scanning calorimetry or DSC" mentioned in the present invention refers to measuring the temperature difference and heat flow difference between a sample and a reference object during the process of heating or maintaining the sample at a constant temperature, so as to characterize all physical and chemical changes related to thermal effects and obtain phase change information of the sample.
[0202] The drying temperature in the present invention is generally 25° C. to 100° C., preferably 40° C. to 70° C., and the drying can be performed under normal pressure or reduced pressure.
[0203] The method of the present invention is described below by means of specific examples. It should be understood that these examples are used to illustrate the basic principles, main features and advantages of the present invention, and the present invention is not limited to the scope of the following examples. The implementation conditions adopted in the examples can be further adjusted according to specific requirements. The implementation conditions not specified are generally the conditions in routine experiments.
[0204] The abbreviations used in the present invention are explained as follows:
[0205] XRPD: X-ray powder diffraction
[0206] DSC: Differential Scanning Calorimetry
[0207] TGA: Thermogravimetric analysis
[0208] DVS: Dynamic Water Sorption
[0209] HPLC: High Performance Liquid Chromatography
[0210] Detection instruments and methods
[0211] X-ray powder diffraction (XRPD)
[0212] Crystalline analysis of the samples was performed using a Bruker D8 ADVANCE X-ray powder diffractometer (using Cu-Kα radiation). The 2θ scanning angle ranged from 3° to 42°, with a scanning step size of 0.02° and a scanning time of 0.05 s per step. The light tube voltage and current were 40 kV and 40 mA, respectively. During sample preparation, an appropriate amount of sample was placed on a sample tray and flattened with a glass slide or other tool to ensure a smooth surface.
[0213] Thermogravimetric analysis (TGA)
[0214] The samples were analyzed using a TA Instruments TGA Discovery 550. The samples were placed in a tared aluminum pan, weighed automatically by the system, and then heated to the specified temperature at a rate of 10°C / min under nitrogen.
[0215] Differential Scanning Calorimetry (DSC)
[0216] The samples were analyzed using a TA Instruments Discovery DSC 25. 2-10 mg of sample was weighed and placed in a sample loading pan, and the sample was heated to the designated temperature at a rate of 10°C / min under the protection of nitrogen (50 ml / min).
[0217] Dynamic Water Sorption Analysis (DVS)
[0218] Samples were analyzed using an Intrinsic DVS (System Measurement System UK). The test sample size was approximately 20-30 mg. The test chamber temperature was controlled at 25 ± 1°C, and the relative humidity was increased from 0% to 90% and then decreased to 0% at a rate of 10% / h. Mass data were recorded every 20 seconds.
[0219] High-performance liquid chromatography (HPLC)
[0220] Solubility and stability tests were performed using an Agilent 1260 HPLC.
[0221] The compound represented by formula (I) of the present invention can be prepared according to the existing technology, for example, according to the method described in WO2022007882A1.
[0222] Example 1: Preparation of Crystal Form A of the Compound Represented by Formula (I)
[0223] Approximately 500 mg of the compound represented by formula (I) was weighed into a 100 ml round-bottom flask, and 4 ml of 1,4-dioxane was added to dissolve it. Then, 36 ml of the antisolvent, isopropanol, was quickly added. The mixture was stirred under magnetic force for 5 hours, cooled on dry ice, and filtered. The resulting solid was dried overnight at 50°C to obtain the product. X-ray powder diffraction analysis confirmed that the product was Form A. The XRPD spectrum is shown in Figure 1, and the positions of its characteristic peaks are shown in Table 1. The DSC spectrum showed an endothermic peak at 182.72°C.
[0224] Table 1: XRPD diffraction peak data of Form A
[0225] Example 2: Preparation of Crystal Form B of the Compound Represented by Formula (I)
[0226] Approximately 500 mg of the compound represented by formula (I) was weighed into a 100 ml round-bottom flask, and 4 ml of 1,4-dioxane was added to dissolve it. Then, 36 ml of the antisolvent acetonitrile was quickly added. The mixture was stirred under magnetic force for 5 hours, cooled on dry ice, and filtered. The resulting solid was dried overnight at 50°C to obtain the product. X-ray powder diffraction analysis confirmed that the product was Form B. The XRPD spectrum is shown in Figure 3, and the positions of its characteristic peaks are shown in Table 2. The DSC spectrum showed an endothermic peak at 184.17°C.
[0227] Table 2: XRPD diffraction peak data of Form B
[0228] Example 3: Preparation of Crystal Form C of the Compound Represented by Formula (I)
[0229] Approximately 500 mg of the compound represented by formula (I) was weighed into an 8 ml glass vial, and 4 ml of methyl tert-butyl ether was added to prepare a suspension. The suspension was stirred at 50°C for 2 days. The resulting solid was then dried at 50°C overnight to obtain the product. X-ray powder diffraction analysis confirmed that the product was Form C. The XRPD spectrum is shown in Figure 5, and the positions of its characteristic peaks are shown in Table 3. The DSC spectrum showed an endothermic peak at 188.83°C.
[0230] Table 3: XRPD diffraction peak data of Form C
[0231] Example 4: Preparation of Crystal Form D of the Compound Represented by Formula (I)
[0232] Approximately 100 mg of the compound represented by formula (I) was weighed into a liquid phase vial. The vial was then placed open into a larger vial containing 30 mL of 1,4-dioxane. The vial was then sealed and allowed to stand at room temperature for 7 days before the solid was removed. X-ray powder diffraction analysis revealed the product to be Form D. The XRPD spectrum is shown in Figure 7, and the positions of its characteristic peaks are shown in Table 4. The DSC spectrum revealed an endothermic peak at 182.91°C.
[0233] Table 4: XRPD diffraction peak data of Form D
[0234] Example 5: Preparation of Crystal Form E of the Compound Represented by Formula (I)
[0235] Approximately 200 mg of the compound represented by formula (I) was weighed into a 4 ml glass vial. 1.5 ml of 1,4-dioxane was added to dissolve the mixture. The mixture was stirred in an ice-water mixture for 5 hours, then filtered. The resulting solid was dried at 50°C overnight to obtain the product. X-ray powder diffraction analysis confirmed that the product was Form E. The XRPD spectrum is shown in Figure 9, and the positions of its characteristic peaks are shown in Table 5. The DSC spectrum showed an endothermic peak at 98.11°C.
[0236] Table 5: XRPD diffraction peak data of Form E
[0237] Example 6: Preparation of the p-toluenesulfonate salt of the compound represented by formula (I) in Form I
[0238] Approximately 50 mg of the compound represented by formula (I) was weighed into a 4 mL vial. 2 mL of ethyl acetate was added, resulting in a turbid solution. The vial was transferred to dry ice and 1.2 eq of p-toluenesulfonic acid monohydrate was added. After stirring at room temperature for 30 minutes, the solution became clear, but with sticky material attached to the walls. After stirring for 2 hours, a white solid precipitated. After stirring overnight, the product was filtered and dried to obtain the product. X-ray powder diffraction analysis confirmed that the product was the p-toluenesulfonate salt Form I of the compound represented by formula (I). The XRPD spectrum is shown in Figure 11, and the positions of its characteristic peaks are shown in Table 6. The DSC spectrum showed an endothermic peak at 198.08°C.
[0239] Table 6: XRPD diffraction peak data of the p-toluenesulfonate salt of the compound represented by formula (I) Form I
[0240] Example 7: Preparation of the p-toluenesulfonate II crystalline form of the compound represented by formula (I)
[0241] Approximately 4000 mg of the compound represented by formula (I) was weighed into a 200 mL round-bottom flask and 160 mL of ethyl acetate was added. The solution was turbid and white. The round-bottom flask was transferred to ice-ethanol and 1.2 eq of p-toluenesulfonic acid monohydrate was added in multiple portions. The solution turned from white to yellow. The solution was stirred in the ice-ethanol system and the temperature was naturally raised to room temperature. During this process, a yellow sticky substance adhered to the bottom. As the stirring time was prolonged, the yellow sticky substance gradually disappeared and the system slowly turned white. After stirring overnight, the solution was filtered, rinsed with ice-cold EA, and then dried at 50°C overnight to obtain the product. X-ray powder diffraction analysis showed that the product was the p-toluenesulfonate salt II crystalline form of the compound represented by formula (I). The XRPD spectrum is shown in Figure 13, and the positions of its characteristic peaks are shown in Table 7. The DSC spectrum showed an endothermic peak of 238.78°C.
[0242] Table 7: XRPD diffraction peak data of the p-toluenesulfonate II crystal form of the compound represented by formula (I)
[0243] Example 8: Preparation of Hydrochloride Form I of the Compound of Formula (I)
[0244] Approximately 50 mg of the compound represented by Formula (I) was weighed into a 4 mL vial. 1 mL of tetrahydrofuran was added. Once the solution clarified, the vial was transferred to dry ice and 2.2 eq of hydrochloric acid was added. After stirring at room temperature for 2 hours, a solid precipitated. After stirring overnight, the solid was filtered and dried to obtain the product. X-ray powder diffraction analysis confirmed that the product was the hydrochloride salt Form I of the compound represented by Formula (I). The XRPD spectrum is shown in Figure 19, and the positions of its characteristic peaks are shown in Table 8. The DSC spectrum showed endothermic peaks at 147.18°C and 181.01°C.
[0245] Table 8: XRPD diffraction peak data of the hydrochloride salt form I of the compound represented by formula (I)
[0246] Example 9: Preparation of the hydrochloride II crystal form of the compound represented by formula (I)
[0247] Approximately 50 mg of the compound represented by Formula (I) was weighed into a 4 mL vial. 1 mL of a 1:1 dichloromethane:ethanol mixture was added. Once the solution clarified, the vial was transferred to dry ice and 2.2 eq of hydrochloric acid was added. After stirring at room temperature overnight, the mixture was left open for evaporation with stirring. After a solid precipitated, it was stirred for approximately 4 hours, filtered, and dried to obtain the product. X-ray powder diffraction analysis confirmed that the product was the hydrochloride salt Form II of the compound represented by Formula (I). The XRPD spectrum is shown in Figure 21, and the positions of its characteristic peaks are shown in Table 9. The DSC spectrum showed endothermic peaks at 188.19°C and 221.47°C.
[0248] Table 9: XRPD diffraction peak data of the hydrochloride II crystal form of the compound represented by formula (I)
[0249] Example 10: Preparation of Sulfate Crystal Form I of the Compound Represented by Formula (I)
[0250] Approximately 25 mg of the compound represented by formula (I) was weighed into a 4 mL vial, 1 mL of acetone was added, the vial was transferred to dry ice, 1.2 eq of sulfuric acid was added, and the mixture was stirred at room temperature for 2 hours. The temperature was raised to 50°C and stirred overnight. The mixture was cooled to room temperature and filtered and dried to obtain the product. X-ray powder diffraction analysis confirmed that the product was the sulfate salt Form I of the compound represented by formula (I). The XRPD spectrum is shown in Figure 23, and the positions of its characteristic peaks are shown in Table 10. The DSC spectrum showed an endothermic peak at 197.63°C.
[0251] Table 10: XRPD diffraction peak data of the sulfate salt of the compound represented by formula (I)
[0252] Example 11: Preparation of Phosphate I Crystalline Form of the Compound Represented by Formula (I)
[0253] Approximately 500 mg of the compound represented by formula (I) was weighed into a 50 mL round-bottom flask. 20 mL of ethyl acetate was added. The solution became turbid. The vial was transferred to dry ice and 1.2 eq of phosphoric acid was added. After stirring at room temperature for 1 hour, the solution was transferred to 50°C and stirred. After approximately 5 minutes, the solution became clear, but a sticky solid mass appeared at the bottom. After 30 minutes, a white solid precipitated. Stirring was continued for 4 hours, the temperature was allowed to cool naturally to room temperature, and the mixture was stirred overnight. The product was filtered and dried to obtain the product. X-ray powder diffraction analysis confirmed that the product was the phosphate salt Form I of the compound represented by formula (I). The XRPD spectrum is shown in Figure 25, and the positions of its characteristic peaks are shown in Table 11. The DSC spectrum showed an endothermic peak at 193.16°C.
[0254] Table 11: XRPD diffraction peak data of the phosphate salt of the compound represented by formula (I)
[0255] Example 12: Preparation of Form I of the Methanesulfonate Salt of the Compound of Formula (I)
[0256] Approximately 50 mg of the compound represented by Formula (I) was weighed into a 4 mL vial and 1 mL of tetrahydrofuran was added. The solution became cloudy and clear. The vial was transferred to dry ice and 2.2 eq of methanesulfonic acid was added. After stirring at room temperature for 4 hours, the solution was heated to 50°C and stirred. The temperature was allowed to cool naturally to room temperature, then the solution was left to evaporate with stirring. After solids precipitated, they were stirred for 4 hours, filtered, and dried to obtain the product. X-ray powder diffraction analysis confirmed that the product was the mesylate salt Form I of the compound represented by Formula (I). The XRPD spectrum is shown in Figure 27, and the positions of its characteristic peaks are shown in Table 12. The DSC spectrum showed an endothermic peak at 132.42°C.
[0257] Table 12: XRPD diffraction peak data of the mesylate salt form I of the compound represented by formula (I)
[0258] Example 13: Preparation of Form I of the Benzenesulfonate Salt of the Compound of Formula (I)
[0259] Weigh approximately 500 mg of the compound represented by formula (I) into a 50 mL round-bottom flask and add 20 mL of ethyl acetate. The solution becomes turbid. Transfer the vial to dry ice and add 1.2 eq of benzenesulfonic acid. After stirring at room temperature for 30 minutes, the solution becomes clear. Transfer to 50°C and stir. After about 20 minutes, the solution becomes clear and a white solid precipitates. Continue stirring for 4 hours, then cool to room temperature and stir overnight. Filter and dry to obtain the product. X-ray powder diffraction analysis shows that the product is the benzenesulfonate salt Form I of the compound represented by formula (I). The XRPD spectrum is shown in Figure 29, and the positions of its characteristic peaks are shown in Table 13. The DSC spectrum shows an endothermic peak of 128.60°C.
[0260] Table 13: XRPD diffraction peak data of benzenesulfonate salt form I of the compound represented by formula (I)
[0261] Example 14: Stability of Forms B and C of the Compound of Formula (I)
[0262] A certain amount of Form B and Form C of the compound represented by Formula (I) was weighed into liquid phase vials, preparing nine portions of each. These were placed in stability chambers at 60°C, 80°C, 25°C, 60% RH, and 40°C, 75% RH, as well as under light exposure. Stability was measured at 60°C for one week and two weeks, at 80°C for one day under light exposure for 10 days, and at 25°C, 60% RH and 40°C, 75% RH for two and four weeks. The crystal form and purity of the solids were also determined. The results are shown in Table 14.
[0263] Table 14: Stability test results of crystal form B and crystal form C of the compound represented by formula (I)
[0264] Stability test results indicate that, in terms of physical stability, Forms B and C exhibited no changes in crystalline form under various test conditions. Regarding chemical stability, Form B exhibited little degradation under all other conditions, except for a 0.51% degradation after 10 days of light exposure. During the stability test, the color of Forms B and C samples changed from off-white to pale yellow under light exposure, while there was no significant color change under other conditions.
[0265] Example 15: Suspension competition test of crystal forms A, B and C of the compound represented by formula (I)
[0266] Appropriate amounts of active pharmaceutical ingredient (API), Form A, Form B, and Form C, were weighed and placed in 1 mL of the corresponding solvent. The mixture was stirred at 25°C or 50°C for 3 days or 7 days, and the crystal stability was evaluated. The results are shown in Table 15.
[0267] Table 15: Suspension competition test results of crystal forms A, B and C
[0268] Competitive beating experiments with suspensions of Forms A, B, and C revealed that Form B was converted to Form B in ethanol, acetonitrile, and isopropanol, and was mostly converted to Form B in water and methyl tert-butyl ether. This indicates that Form B is more stable than Forms A and C within the temperature range of 25°C to 50°C.
[0269] Example 16. Evaluation of the grinding test of the B crystal form of the compound represented by formula (I)
[0270] A certain amount of Form B of the compound represented by Formula (I) was placed in a mortar, 1-2 drops of solvent (H₂O or EtOH) were added, and the mixture was ground for 5 minutes before XRPD analysis. As shown in Figure 17, the resulting solids were consistent with Form B, except for a decrease in crystallinity.
[0271] Example 17: Tablet test evaluation of Form B of the compound represented by formula (I)
[0272] A tableting experiment was conducted using a certain amount of Form B of the compound represented by Formula (I). An appropriate amount of Form B powder was compressed at 10 MPa for three minutes and then analyzed by XRPD. As shown in Figure 18, the resulting solid was consistent with Form B, except for a decrease in crystallinity.
[0273] Example 18: Evaluation of the polymer induction test of the B-type of the compound represented by formula (I)
[0274] About 10 mg of Form B of the compound represented by formula (I) was weighed into 1 mL of solvent, and about 10% (mass ratio) of a polymer was added. The mixture was stirred at room temperature for 24 hours and then filtered. The resulting solid was subjected to XRPD testing. Table 16 shows that the solids induced by the polymer were all Form B, indicating that Form B has good physical stability.
[0275] Table 16: Experimental conditions and results of induction of crystal form B polymer
[0276] Example 19: Stability of Phosphate Form I, Benzenesulfonate Form I, and p-Toluenesulfonate Form II of the Compound of Formula (I)
[0277] A certain amount of phosphate salt form I, benzenesulfonate salt form I and p-toluenesulfonate salt form II samples of the compound represented by formula (I) were placed in a stability test chamber and taken out after a certain period of time for HPLC and XRPD testing.
[0278] Test conditions: 25°C / 60% RH, 40°C / 75% RH for two and four weeks; 60°C for one and two weeks; 80°C for one day; light intensity: 1.2M lux. The results are shown in Table 17.
[0279] Table 17: Stability test results of phosphate I crystal form, benzenesulfonate I crystal form and p-toluenesulfonate II crystal form
[0280] The results show that under illumination conditions of -1.2M lux, Form I phosphate and Form I benzenesulfonate degraded by 1.06% and 3.11%, respectively, while Form II p-toluenesulfonate degraded by only 0.06%. At 60°C for one week, two weeks, and 80°C for one day, benzenesulfonate degraded by 0.31%, 0.34%, and 0.3%, respectively, while Form I phosphate and Form II p-toluenesulfonate showed no significant degradation. Under other conditions (25°C / 60% RH, 40°C / 75% RH for two weeks, and four weeks), Form I phosphate, Form I benzenesulfonate, and Form II p-toluenesulfonate showed almost no degradation. The crystal forms of the phosphate salt form I and the p-toluenesulfonate salt form II did not change under the existing test conditions (25°C / 60% RH, 40°C / 75% RH for two weeks and four weeks; 60°C for one week and two weeks; 80°C for one day; light -1.2M lux). However, the crystallinity of the benzenesulfonate salt form I decreased under the conditions of 25°C / 60% RH for two weeks and four weeks, and the crystal form changed under other conditions.
[0281] Example 20: Hygroscopicity of the p-toluenesulfonate II crystalline form of the compound represented by formula (I)
[0282] The hygroscopicity of Form II p-toluenesulfonate was evaluated by dynamic moisture sorption testing at 25°C between 0% and 90% RH. The DVS results are shown in Figure 15. The p-toluenesulfonate Form II exhibited a moisture sorption weight gain of 0.5731% at 80% RH, indicating that the product is slightly hygroscopic. The p-toluenesulfonate Form II exhibited no change in crystalline form before and after the DVS test.
[0283] Example 21: Feasibility Study on the Formulation Process of the Crystalline Form II of the p-Toluenesulfonate Salt of the Compound Represented by Formula (I)
[0284] A certain amount of p-toluenesulfonate II crystal was heated (225°C), ground (2 min), ground in the dark, and pressed into tablets, and then its XRPD was measured, and the crystal form did not change.
[0285] Example 22: Oral Pharmacokinetic Study of the Free Base Form B and the p-Toluenesulfonate Form II of the Compound of Formula (I) in Rats
[0286] The pharmacokinetics (PK) of the free base Form B and the p-toluenesulfonate Form II were evaluated in SD rats following oral gavage (300 mg / kg and 1000 mg / kg, respectively). The vehicle was 15% vitamin E TPGS + 10% Transcutol HP + 45% PEG 400 + 30% water. Blood was collected before dosing and at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 32 hours, and 48 hours after dosing. The pharmacokinetic parameters in rat plasma are shown in Tables 18 and 19.
[0287] Table 18: Results of oral pharmacokinetic study of the free base B form of the compound represented by formula (I) in rats
[0288] Table 19: Results of oral pharmacokinetic study on the p-toluenesulfonate II crystal form of the compound represented by formula (I) in rats
[0289] It should be understood that the above embodiments are exemplary and are not intended to encompass all possible implementations of the claims. Various modifications and variations may be made to the above embodiments without departing from the scope of the present invention. Similarly, the various technical features of the above embodiments may be arbitrarily combined to form additional embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments merely illustrate several implementations of the present invention and do not limit the scope of protection of the patent of the present invention.
Claims
1. Crystal form A of the compound represented by formula (I), It is characterized by: The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 6.938, 7.606, 9.256, 12.359 and 15.793; preferably, characteristic peaks are present at 6.938, 7.606, 9.256, 9.912, 11.482, 12.359, 15.793 and 16.368; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG1 .
2. Crystal Form B of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 7.593, 11.516, 13.092, 16.526 and 19.247; preferably, characteristic peaks are present at 7.593, 9.977, 11.516, 13.092, 15.380, 16.526, 19.247, 20.095, 23.854, 26.355, 27.639 and 29.809; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG3 .
3. Crystal Form C of the compound represented by formula (I), It is characterized by: The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 10.463, 10.666, 18.572, 20.708, 22.028 and 23.848; preferably at 10.463, 10.666, 13.970, 14.482, 15.220, 15.519, 17.747, 18.572, 20.708, 22.028 and 23.848 There are characteristic peaks; more preferably, there are characteristic peaks at 10.463, 10.666, 12.408, 13.970, 14.482, 15.220, 15.519, 17.747, 18.572, 20.708, 21.384, 22.028, 22.851, 23.848 and 25.788; most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 5.
4. Crystal form D of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 9.922, 11.176, 15.797, 16.230, 18.691 and 19.404; preferably at 7.514, 9.922, 11.176, 12.937, 15.797, 16.230, 18.691, 19.404, 20.310 and 21.224 There are characteristic peaks; more preferably, there are characteristic peaks at 7.514, 9.922, 11.176, 12.937, 15.797, 16.230, 17.219, 18.691, 19.404, 20.310, 21.224, 23.476, 24.003 and 24.627; most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 7.
5. Crystal form E of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 6.889, 9.043, 13.463, 15.828, 16.891 and 18.650; preferably, characteristic peaks at 5.164, 6.889, 8.818, 9.043, 13.463, 13.722, 15.828, 16.394, 16.891, 18.650 and 20.464 More preferably, there are characteristic peaks at 5.164, 6.889, 8.818, 9.043, 10.541, 13.463, 13.722, 15.828, 16.394, 16.891, 18.083, 18.650, 20.464, 22.201, 22.871 and 23.627; Most preferably, the X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ is shown in Figure 9.
6. A pharmaceutically acceptable salt of a compound represented by formula (I), characterized in that: The pharmaceutically acceptable salt is selected from hydrochloride, sulfate, phosphate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, 7. The pharmaceutically acceptable salt according to claim 6, characterized in that The chemical ratio of the compound represented by formula (I) to the acid molecule or anion is 1:0.5 to 1:3, preferably 1:0.5, 1:1, 1:2 or 1:3, and most preferably 1:1 or 1:
2.
8. The pharmaceutically acceptable salt according to claim 6 or 7, characterized in that The pharmaceutically acceptable salt is p-toluenesulfonate.
9. Form I of the p-toluenesulfonate salt of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 3.733, 7.394, 16.080 and 19.153; preferably, characteristic peaks at 3.733, 7.394, 11.052, 14.739, 15.496, 16.080, 19.153, 22.059 and 28.088; more preferably, characteristic peaks at 3.733, 7.3 There are characteristic peaks at 94, 9.755, 11.052, 11.438, 12.185, 12.726, 13.220, 14.739, 15.496, 16.080, 17.180, 18.240, 19.153, 22.059 and 28.088; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 11.
10. Crystalline Form II of the p-toluenesulfonate salt of the compound represented by formula (I), It is characterized by: The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 12.163, 14.065, 17.303, 19.416, 20.532 and 22.762; preferably, characteristic peaks at 3.780, 7.640, 10.191, 10.897, 12.163, 12.781, 14.065, 16.237, 17.303, 19.416, 20.532 and 22.762; more preferably Characteristic peaks are selected at 3.780, 7.640, 10.191, 10.897, 12.163, 12.781, 14.065, 15.837, 16.237, 16.954, 17.303, 19.000, 19.416, 20.532, 20.906, 21.961, 22.286 and 22.762; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 13.
11. Crystal Form I of the hydrochloride salt of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 8.761, 9.480, 10.635 and 17.422; preferably, characteristic peaks are present at 8.761, 9.480, 10.635, 15.425, 16.788, 17.422 and 22.750; and most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 19 .
12. Crystalline Form II of the hydrochloride salt of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 6.985, 11.691, 14.025, 16.680 and 17.536; preferably, characteristic peaks are present at 6.985, 11.691, 14.025, 16.680, 17.536, 18.259, 19.185, 21.121, 21.895 and 23.548; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 21 .
13. Crystal Form I of the sulfate salt of the compound represented by formula (I), It is characterized by: The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 3.326, 6.485, 12.875, 13.879 and 19.273; preferably, characteristic peaks at 3.326, 6.485, 8.601, 12.875, 13.879, 16.915, 17.835, 19.273, 19.920 and 22.486; more preferably, characteristic peaks at 3.3 There are characteristic peaks at 26, 6.485, 8.601, 12.003, 12.875, 13.879, 14.315, 15.454, 16.087, 16.915, 17.835, 19.273, 19.920, 22.486, 23.727 and 25.010; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 23.
14. Crystal form I of the phosphate salt of the compound represented by formula (I), It is characterized by: The X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ has characteristic peaks at 3.436, 6.784, 16.868, 18.478 and 20.264; preferably, characteristic peaks are present at 3.436, 6.028, 6.784, 13.507, 15.360, 16.868, 18.478, 20.264, 23.661 and 30.556; most preferably, the X-ray powder diffraction pattern expressed in terms of a diffraction angle of 2θ is shown in FIG. 25 .
15. Crystal form I of the methanesulfonate of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 7.945, 8.540, 12.203, 13.820 and 20.863; preferably, characteristic peaks at 7.945, 8.540, 10.316, 10.621, 11.507, 12.203, 13.820, 14.579, 15.964 and 20.863; more preferably There are characteristic peaks at 7.945, 8.540, 10.316, 10.621, 11.507, 12.203, 13.820, 14.579, 15.964, 17.640, 20.284, 20.863, 23.234, 23.888 and 26.418; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 27.
16. Form I of the benzenesulfonate salt of the compound represented by formula (I), It is characterized in that The X-ray powder diffraction pattern expressed as a diffraction angle 2θ has characteristic peaks at 5.268, 6.306, 13.796, 15.768 and 18.673; preferably, there are characteristic peaks at 5.268, 6.306, 6.865, 13.796, 15.023, 15.768, 18.673, 21.035, 21.892 and 22.608; more preferably, there are characteristic peaks at 5. There are characteristic peaks at 268, 6.306, 6.865, 9.398, 11.030, 12.049, 13.796, 15.023, 15.768, 16.228, 17.946, 18.673, 20.835, 21.035, 21.892 and 22.608; the most preferred X-ray powder diffraction pattern expressed in diffraction angle 2θ is shown in Figure 29.
17. The crystalline form according to any one of claims 1 to 5 and 9 to 16, characterized in that The 2θ angle error range is ±0.
20.
18. The method for preparing the crystal form A of the compound represented by formula (I) according to claim 1, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 1, dissolving the compound, adding solvent 2, and crystallizing the compound; Preferably, the solvent 1 is selected from ether solvents, preferably one or more of ethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane, more preferably 1,4-dioxane; Preferably, the solvent 2 is selected from alcohol solvents, preferably C 1-4 The alcohol is more preferably one or more of methanol, ethanol and isopropanol, and most preferably isopropanol.
19. The method for preparing the crystal form B of the compound represented by formula (I) according to claim 2, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 3, dissolving the mixture, adding solvent 4, and crystallizing the mixture; Preferably, the solvent 3 is selected from ether solvents, preferably one or more of ethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane, more preferably 1,4-dioxane; Preferably, the solvent 4 is selected from nitrile solvents, preferably one or more of acetonitrile, propionitrile and valeronitrile, more preferably acetonitrile.
20. The method for preparing the crystal form C of the compound represented by formula (I) according to claim 3, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with a solvent 5, suspending, stirring, and filtering to obtain a filter cake; Preferably, the solvent 5 is selected from ether solvents, preferably one or more of ethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and methyl tert-butyl ether, more preferably methyl tert-butyl ether.
21. The method for preparing the crystal form D of the compound represented by formula (I) according to claim 4, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with a solvent 6, sealing, placing, and filtering to obtain a filter cake; Preferably, the solvent 6 is selected from ether solvents, preferably one or more of ethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane, more preferably 1,4-dioxane.
22. The method for preparing the E crystal form of the compound represented by formula (I) according to claim 5, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 7, dissolving the mixture, cooling the mixture to room temperature, and crystallizing the mixture; Preferably, the solvent 7 is selected from ether solvents, preferably one or more of ethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and 1,4-dioxane, more preferably 1,4-dioxane.
23. The method for preparing the pharmaceutically acceptable salt according to any one of claims 6 to 8, characterized in that: The method comprises the following steps: a step of reacting the compound of formula (I) with an acid to form a salt.
24. The method according to claim 23, wherein The solvent used in the salt-forming reaction is selected from one or more of alcohol, ether, ester, halogenated alkane, ketone and water, preferably one or more of tetrahydrofuran, dichloromethane, ethanol, ethyl acetate, acetone and water.
25. The method for preparing the crystalline form I of the p-toluenesulfonate salt of the compound represented by formula (I) according to claim 9, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 8, placing the system in dry ice, adding p-toluenesulfonic acid monohydrate, stirring at room temperature, and crystallizing; Preferably, the solvent 8 is selected from ester solvents, preferably one or more of ethyl acetate, methyl acetate, butyl acetate and isobutyl acetate, more preferably ethyl acetate.
26. The method for preparing the crystal form II of the p-toluenesulfonate salt of the compound represented by formula (I) according to claim 10, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 9, placing the system in ice-ethanol, adding monohydrated p-toluenesulfonic acid, stirring overnight, and crystallizing; Preferably, the solvent 9 is selected from ester solvents, preferably one or more of ethyl acetate, methyl acetate, butyl acetate and isobutyl acetate, more preferably ethyl acetate.
27. The method for preparing the crystalline form I of the hydrochloride salt of the compound represented by formula (I) according to claim 11, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with a solvent 10, placing the system in dry ice, adding hydrochloric acid, stirring at room temperature, crystallizing, stirring overnight, and filtering; Preferably, the solvent 10 is selected from ether solvents, preferably one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and tetrahydrofuran, more preferably tetrahydrofuran.
28. The method for preparing the crystal form II of the hydrochloride salt of the compound represented by formula (I) according to claim 12, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with a solvent 11, placing the system in dry ice, adding hydrochloric acid, stirring at room temperature, evaporating the solvent in an open state, stirring after precipitating a solid, and filtering; Preferably, the solvent 11 is selected from a mixed solvent of halogenated alkanes and alcohol solvents, preferably a mixed solvent of halogenated alkanes selected from dichloromethane, chloroform, carbon tetrachloride and 1,2-dichloroethane and an alcohol solvent selected from methanol, ethanol and isopropanol, more preferably a mixed solvent of dichloromethane and ethanol.
29. The method for preparing the crystal form I of the sulfate salt of the compound represented by formula (I) according to claim 13, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 12, placing the system in dry ice, adding sulfuric acid, stirring at room temperature, heating to 50° C. and stirring overnight, cooling to room temperature, and filtering; Preferably, the solvent 12 is selected from ketone solvents, preferably one or more of acetone, butanone, pentanone, hexanone and cyclohexanone, more preferably acetone.
30. The method for preparing the crystal form I of the phosphate of the compound represented by formula (I) according to claim 14, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 13, placing the system in dry ice, adding phosphoric acid, stirring at room temperature, heating to 50° C. and stirring to allow crystals to precipitate, continuing stirring, cooling to room temperature and stirring overnight, and filtering; Preferably, the solvent 13 is selected from ester solvents, preferably one or more of ethyl acetate, methyl acetate, butyl acetate and isobutyl acetate, more preferably ethyl acetate.
31. The method for preparing the crystal form I of the mesylate salt of the compound represented by formula (I) according to claim 15, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 14, placing the system in dry ice, adding methanesulfonic acid, stirring at room temperature, heating to 50° C. with stirring, cooling to room temperature with open air for evaporation with stirring, crystallization, stirring, and filtering; Preferably, the solvent 14 is selected from ether solvents, preferably one or more of diethyl ether, propyl ether, butyl ether, anisole, petroleum ether, isopropyl ether and tetrahydrofuran, more preferably tetrahydrofuran.
32. The method for preparing the crystalline form I of the benzenesulfonate salt of the compound represented by formula (I) according to claim 16, characterized in that: The method comprises the following steps: mixing the compound represented by formula (I) with solvent 15, placing the system in dry ice, adding benzenesulfonic acid, stirring at room temperature, heating to 50° C. and stirring to allow crystals to precipitate, continuing stirring, cooling to room temperature and stirring overnight, and filtering; Preferably, the solvent 15 is selected from ester solvents, preferably one or more of ethyl acetate, methyl acetate, butyl acetate and isobutyl acetate, more preferably ethyl acetate.
33. A method comprising: forming a pharmaceutically acceptable salt of the compound of formula (I) according to claim 1, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 2, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 3, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 4, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 5, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 6, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 9, a pharmaceutically acceptable salt of the compound of formula (I) according to claim 10, or a pharmaceutically acceptable salt of the compound of formula (I) according to claim 11. The pharmaceutical composition is prepared by the crystal form II of the p-toluenesulfonate of the compound represented by formula (I) according to claim 11, the crystal form I of the hydrochloride of the compound represented by formula (I) according to claim 12, the crystal form I of the sulfate of the compound represented by formula (I) according to claim 13, the crystal form I of the phosphate of the compound represented by formula (I) according to claim 14, the crystal form I of the methanesulfonate of the compound represented by formula (I) according to claim 15, or the crystal form I of the benzenesulfonate of the compound represented by formula (I) according to claim 16.
34. A pharmaceutical composition comprising: Form A of the compound of formula (I) according to claim 1; Form B of the compound of formula (I) according to claim 2; Form C of the compound of formula (I) according to claim 3; Form D of the compound of formula (I) according to claim 4; Form E of the compound of formula (I) according to claim 5; a pharmaceutically acceptable salt of the compound of formula (I) according to any one of claims 6 to 8; Form I of the p-toluenesulfonate salt of the compound of formula (I) according to claim 9; or Form I of the p-toluenesulfonate salt of the compound of formula (I) according to claim 10. The crystal form II of the p-toluenesulfonate of the compound represented by formula (I) according to claim 11, the crystal form I of the hydrochloride of the compound represented by formula (I) according to claim 12, the crystal form I of the hydrochloride of the compound represented by formula (I) according to claim 13, the crystal form I of the sulfate of the compound represented by formula (I) according to claim 13, the crystal form I of the phosphate of the compound represented by formula (I) according to claim 14, the crystal form I of the methanesulfonate of the compound represented by formula (I) according to claim 15, or the crystal form I of the benzenesulfonate of the compound represented by formula (I) according to claim 16, and at least one pharmaceutically acceptable excipient.
35. A method for preparing a pharmaceutical composition, comprising: preparing Form A of the compound of formula (I) according to claim 1, Form B of the compound of formula (I) according to claim 2, Form C of the compound of formula (I) according to claim 3, Form D of the compound of formula (I) according to claim 4, Form E of the compound of formula (I) according to claim 5, a pharmaceutically acceptable salt of the compound of formula (I) according to any one of claims 6 to 8, Form I of the p-toluenesulfonate salt of the compound of formula (I) according to claim 9, or Form I of the p-toluenesulfonate salt of the compound of formula (I) according to claim 10. The step of mixing the crystal form II of the p-toluenesulfonate of the compound represented by formula (I) according to claim 11, the crystal form I of the hydrochloride of the compound represented by formula (I) according to claim 12, the crystal form I of the sulfate of the compound represented by formula (I) according to claim 13, the crystal form I of the phosphate of the compound represented by formula (I) according to claim 14, the crystal form I of the methanesulfonate of the compound represented by formula (I) according to claim 15, or the crystal form I of the benzenesulfonate of the compound represented by formula (I) according to claim 16 with at least one pharmaceutically acceptable excipient.
36. Crystalline Form A of the compound of formula (I) according to claim 1, Crystalline Form B of the compound of formula (I) according to claim 2, Crystalline Form C of the compound of formula (I) according to claim 3, Crystalline Form D of the compound of formula (I) according to claim 4, Crystalline Form E of the compound of formula (I) according to claim 5, or a pharmaceutically acceptable salt of the compound of formula (I) according to any one of claims 6 to 8, Crystalline Form I of the p-toluenesulfonate salt of the compound of formula (I) according to claim 9, Crystalline Form II of the p-toluenesulfonate salt of the compound of formula (I) according to claim 10, or the hydrochloric acid salt of the compound of formula (I) according to claim 11. The invention relates to a pharmaceutical composition according to claim 33 or 34, or a pharmaceutical composition prepared by the method according to claim 35, in the preparation of a medicament for treating and / or preventing ATX (autotaxin)-related diseases.
37. The use according to claim 36, wherein the ATX-related disease is a fibrotic disease, cancer, a proliferative disease, an inflammatory disease, an autoimmune disease, a respiratory disease, a cardiovascular disease, a neurodegenerative disease, a dermatological disease, a metabolic disease, myelodysplastic syndrome, a disease related to abnormal angiogenesis, or pain, preferably a fibrotic disease, cancer, a dermatological disease, preferably pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), liver fibrosis, scleroderma, renal cancer, pancreatic cancer, or cholestatic pruritus.
